LDX Chart, page-1595

Its Friday, unlikely to see gains today.

I am hoping management provide some positive news in the next week or so ($5M received from Hologic, new distributor in US/AUS, update on some other products they have been assisting in manufacturing). Fact is, if we are just waiting for further uptake of Febridx/Viradx in the US and eventual release of FFN which could not be till end of next year, then nothing is going to improve this in the short term, which is disappointing.

Revenue will drive increase in SP, that means more new deals with other services partners, increased product sales, as well as newer distributors in other markets outside the US.

Otherwise, this is stagnant sailing until then. Very very frustrating for long term holders given where we were.